The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

The Vertex drug is a milestone after a long history of unsuccessful efforts to develop painkillers without the addictive potential of opioids.

BOSTON—Ourania Tatsis, Executive Vice President and Chief Regulatory and Quality Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a $116 billion market cap biotech company currently trading near ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at least as effective and costs only 50 cents a pill? They will if the generic ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

HOUSTON, January 22, 2025--(BUSINESS WIRE)--Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates ...

Shares of Vertex Pharmaceuticals gained about 6% Friday morning, after the pharmaceutical company won U.S. approval for the ...